linjc16/ctgov huggingface dataset:
A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether it is possible to detect changes in the concentration of PP13 in the blood of pregnant women who may go on to develop the complication of preeclampsia later on in the pregnancy, and if these changes can be detected early enough to allow early diagnosis and treatment for prevention of these complications and reduce their damage. This study will test if the PP13 biomarker during the first trimester of pregnancy has the ability to provide assessment of risk for the development of preeclampsia that necessitates delivery before 37 weeks gestation or can predict preeclampsia before 34 weeks gestation.

Detailed Description
-----------------
After obtaining informed consent maternal demographics, vital signs, height, weight, medical history, pregnancy dating, dipstick for urine protein, previous lab results, nuchal translucency results and uterine artery Doppler results (if done) will be obtained. Blood for PP13 will be obtained at 7-13 weeks and optionally at 21-23 weeks. Hospitalization and delivery information will be obtained via a chart review for evidence of preeclampsia.

Official Title
-----------------
A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) In-vitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Preeclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, pregnant females Singleton fetus at 7 0/7 to 13 6/7 weeks gestation Exclusion Criteria: Multi-fetal pregnancy Mental retardation Known fetal anomaly or demise BMI > 35, serious medical condition

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preeclampsia necessitating delivery at gestational age < 37 weeks including HELLP syndrome and eclampsia |  | 37 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal and Neonatal morbidity and mortality and very early preeclampsia necessitating delivery before 34 weeks |  | 34 Weeks, At Delivery |
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Esophageal squamous cell carcinoma is considerably more prevalent in East Asia. Despite of relatively high prevalence of esophageal SCC, prognosis is very poor with limited options of effective chemotherapy regimens. We attempted to identify favorable subgroups of patient who are likely to benefit from 5- fluorouracil/cisplatin(FP) or capecitabine/cisplatin (XP) chemotherapy as first-line treatment.Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy. Clinicopathologic variables and treatment outcome were retrospectively collected. we analysis treatment outcome of palliative chemotherapy in metastatic esophageal squamous cell carcinoma and make prognostic scoring system. The present study represents the largest series to analyze the treatment outcome of FP/XP chemotherapy in metastatic SCC. Risk-adapted stratification of treatment for subgroup of metastatic SCC patients should be actively pursued.

Official Title
-----------------
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients

Conditions
-----------------
Metastatic Esophageal Squamous Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: recurrent, metastatic esophageal SCC received either FP or XP as first-line chemotherapy. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metastatic esophageal squamous cell carcinoma, Fluoropyrimidine/platinum-based first-line chemotherapy, prognosis
Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia

Study Overview
=================
Brief Summary
-----------------
Poor oral hygiene is associated with respiratory pathogen colonization and secondary lung infection.The possible association between oral care and incidence of VAP, and the role of dental plaque, mouth and tracheal colonization have not been firmly established. The investigators' hypothesis was that improving oral care with electrical toothbrushing might be effective in reducing the incidence of VAP.

Official Title
-----------------
Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia

Conditions
-----------------
Ventilator-Associated Pneumonia, Nosocomial Pneumonia, Pneumonia

Intervention / Treatment
-----------------
* Procedure: Toothbrushing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult intubated patients Without evidence of pulmonary infection (randomized within 12h of intubation if they were expected to remain ventilated for longer than 48 hours) Exclusion Criteria: Absence of dental pieces Current diagnosis of pneumonia or massive bronchoaspiration Tracheostomy (or expected within 48 hours) Chlorhexidine allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Raspall<br> | Procedure: Toothbrushing<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventilator-Associated Pneumonia (VAP) |  | 28 days |
Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder

Study Overview
=================
Brief Summary
-----------------
This study is going to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on Borderline Personality Disorder patients symptoms.

Detailed Description
-----------------
There is a great body of literature about the positive effects of rTMS therapy on various psychiatric disorders. In this study we are going to evaluate the effects of high-frequency rTMS over the left dorsolateral prefrontal cortex (DLPFC)region in borderline personality disorder (BPD) patients. patients will be assessed by subjective measures for BPD.

Official Title
-----------------
A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients

Conditions
-----------------
Borderline Personality Disorder

Intervention / Treatment
-----------------
* Device: rTMS
* Device: sham rTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically diagnosed borderline personality disorder according to DSM IV. Exclusion Criteria: Epilepsy Any metal device Psychotic disorders Bipolar mood disorder type 1

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: rTMS intervention group<br>The rTMS intervention group undergo ten session of real TMS therapy. | Device: rTMS<br>* Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC<br>* Other names: repetitive transcranial magnetic stimulation;|
| Placebo Comparator: Sham group<br>Patients will undergo ten session of sham rTMS. | Device: sham rTMS<br>* Patients will undergo ten session of sham rTMS.<br>* Other names: sham repetitive transcranial magnetic stimulation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' reports | changes in subjective measures from baseline to tenth day of treatment | Change from baseline to two weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient's report | change in subjective measures from baseline to 1 month after treatment | Change from baseline to 1 month | 
| Patient's report | change in subjective measures form baseline to 3 month after treatment | Change from baseline to 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Borderline personality disorder, repetitive transcranial magnetic stimulation
Effects of Carvedilol on Cocaine Use in Humans - 11

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine carvedilol effects in response to cocaine.

Detailed Description
-----------------
The purpose of this study was to determine whether carvedilol, and alpha and beta adrenergic blocker, would inhibit the priming effect of cocaine in a laboratory model. A total of 12 subjects were enrolled in this double blind, placebo controlled, outpatient study. After an adaptation session, three experimental sessions were held, 2-9 days apart. On each of 3 experimental sessions, a single oral dose of low (25mg) or high dose of carvedilol (50mg) or placebo were administered. Two hours following carvedilol or placebo treatment, subjects received a priming dose of smoked cocaine, 0.4 mg/kg. during the second part of the session, subjects had the option to earn up to 2 tokens by working on a computer task that could later be exchanged for money or deliveries of cocaine. We proposed that blockage of adrenergic receptors by carvedilol would significantly alter the subjective and physiological effects of cocaine.

Official Title
-----------------
Effects of Carvedilol on Cocaine Use in Humans

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Carvedilol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/Female between 20 and 55. History of smoked or intravenous cocaine use on the average of at least once a week over a 6 month period. current history of good health and normal EKG. Not pregnant as determined by pregnancy screening nor breast feeding, using acceptable birth control methods (e.g. birth control pills diaphragm, condoms plus foam) Exclusion Criteria: Current problems with major psychiatric illnesses including bipolar disorder, schizophrenia, or anxiety disorders. History of major medical illnesses including asthma and chronic obstructive pulmonary disease. Currently on a drug related parole or probation. Treated for chemical dependency withing the past 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Carvedilol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral |  |  | 
| Subjective |  |  | 
| Physiologic measures |  |  |
Proteinuria in Pre and Post Transplant

Study Overview
=================
Brief Summary
-----------------
Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.

Detailed Description
-----------------
This study will retrospectively review patient's medical records for protein in the urine, blood creatinine and kidney biopsy results. Also character of the fluid used to flush the kidney before transplant will be analyzed.

Official Title
-----------------
Evaluation of Recipients With and Without Proteinuria, Pre and Post Kidney Transplantation

Conditions
-----------------
Proteinuria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Kidney transplant recipients Pediatric males and females up to the age of 25 years old. Exclusion Criteria: Transplant recipients other than kidney

Ages Eligible for Study
-----------------
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Explain mechanisms behind the development of proteinuria in patients immediately after receiving a kidney transplant | chart review | through study completion, an average of 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
focal segmental glomerulosclerosis
Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to test the function of a subjects implantable cardioverter defibrillator (ICD) function throughout the duration of their heart surgery. ICD function can be altered during some types of heart surgery such as those when a pump (ventricular assist device - VAD) is implanted. The investigators would like to study the mechanism of device and ICD malfunction.

Detailed Description
-----------------
ICD function is typically measured prior to and after surgery. For the study, the investigators will measure ICD lead function multiple times throughout the surgery as well, to determine if and when device malfunction occurs. ICD lead function is measured noninvasively through a specialized computer the same way it is checked in the clinic. In addition, the investigators will test ICD function as they usually do following surgery.

Official Title
-----------------
Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ages 18 and older Have a wireless implantable cardioverter defibrillator (ICD) and are undergoing VAD implantation or other cardiothoracic surgery. Exclusion Criteria: Patients who are pacemaker dependent children, human fetuses, neonates prisoners will not be included Pregnant women will not be included

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Group - Control Group<br>VAD implantation (study group) or other cardiothoracic surgery (control group) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| observational study to assess potential changes that may occur in the RV ICD lead function during LVAD implantation and what mechanism may cause those changes in RV ICD lead function |  | RV ICD lead function will be measured throughout LVAD placement , at 1 week post LVAD placement, and 3 months post LVAD placement Description: | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Implantable Cardioverter Defibrillator, Ventricular Assist Device
Evaluation of Newborns Presenting With Suspected COVID 19

Study Overview
=================
Brief Summary
-----------------
This study evaluates the newborns who had respiratory symptoms at the neonatal intensive care admission

Official Title
-----------------
Evaluation of Newborns Presenting With Suspected COVID 19: A Single Center Experience

Conditions
-----------------
Viral Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All newborns who had respiratory symptoms at the NICU admission Exclusion Criteria: Congenital abnormalities

Ages Eligible for Study
-----------------
Maximum Age: 1 Month

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>The newborns with covid 19 infection | |
| Group 2<br>The newborns with no covid 19 infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| General Characteristics of the infants with respiratory infection at the NICU admission | Demographical characteristics will be recorded | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
newborn, covid infection, viral infection
Attitudes Towards Buprenorphine and Methadone

Study Overview
=================
Brief Summary
-----------------
Main intention of this study is to find out whether there is a difference between the attitudes towards opioid- substitution of opioid dependent patients under substitution with methadone, buprenorphine or without substitution and their therapists

Detailed Description
-----------------
Attitudes of patients and therapists can influence therapy success in both directions. Not much is known about patients' and their therapists' attitudes towards substitution medication. Our hypothesis is that the attitude towards buprenorphine is more positive than towards methadone even in patients taking methadone. Better knowledge about the influence of attitudes on treatment success could facilitate to adapt therapy to the patients' needs.

Official Title
-----------------
Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone

Conditions
-----------------
Addictive, Opioids

Intervention / Treatment
-----------------
* Other: interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 65 years Opioid-dependent with substitution with buprenorphine, methadone or without substitution Sufficient knowledge of German language Exclusion Criteria: Inability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Buprenorphine<br>opioid-dependent patients with buprenorphine substitution | Other: interview<br>* interview using questionnaires<br>* Other names: questionnaire attitudes toward substitution;|
| methadone<br>opioid-dependent patients substituted with methadone | Other: interview<br>* interview using questionnaires<br>* Other names: questionnaire attitudes toward substitution;|
| no substitution<br>opioid-dependent patients without substitution | Other: interview<br>* interview using questionnaires<br>* Other names: questionnaire attitudes toward substitution;|
| therapists<br>therapists of the patients | Other: interview<br>* interview using questionnaires<br>* Other names: questionnaire attitudes toward substitution;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attitude toward buprenorphine compared over the four groups |  | one time of measurement | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment success; Treatment conditions; Consumption of substances |  | one point of measurement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opioid dependence substitution buprenorphine methadone, substitution